Table 1.

Clinical characteristics and outcomes of patients with glioblastoma reported in the literature who demonstrated reduced contrast enhancement after dexamethasone treatment.

Reference	Age	Presentation	Tumor location	Dexamethasone dose	Initial radiographic change	Time to reoccurrence	Treatment	Outcome
[2]	56 M	Right facial palsy, dysphagia, and unsteady gait	Left frontoparietal lobe	2 mg every 8 hours	Disappearance of tumor and contrast enhancement	3 weeks; reappearance, same location	None	Death immediately after tissue biopsy, ~3 weeks after initial radiographic change
[5]	59 M	Headache and confusion	Left parietal lobe	16 mg every 24 hours	Reduction in contrast enhancement	4 weeks; reappearance, same location	Not reported	Not reported
[4]	61 F	Left hemiparesis, paresthesia	Right temporal lobe, right frontal lobe, splenium	4 mg every 6 hours for 2 weeks	Near-complete resolution of all lesions	4 weeks; increased size, new focus	Radiotherapy	Death ~5 months after initial radiographic change
[7]	53 M	Seizure	Right parietal lobe, corpus callosum	4 mg every 6 hours for 3 weeks	Reduced enhancement in right parietal lobe, increased enhancement in corpus callosum	3 weeks	Radiotherapy	Not reported
[7]	75 M	Confusion, short-term memory loss	Right parietal lobe, posterior corpus callosum	4 mg every 6 hours for 3 weeks	Resolution of right parietal lesion, increased enhancement in splenium	3 weeks	None	Death prior to commencing radiotherapy
This paper	57 F	Short-term memory loss, unsteady gait	Right temporoparietal lobe, splenium	4 mg every 6 hours for 5 days	Reduction in contrast enhancement	2 weeks; increased size, new focus, leptomeningeal spread	Chemotherapy with temozolomide, radiotherapy	Clinically stable 2 months after initial radiographic change